1. Emerging Data on ACS Management From ACC

2. Assessing the Impact of Medication Affordability on Prescribing Patterns and Patient Adherence

3. Background

4. Hypotheses

5. ARTEMIS: Study Design

6. ARTEMIS: Clinicians Are Sensitive to Patient Costs

7. ARTEMIS Non-Persistence of P2Y12 Inhibitor

8. ARTEMIS MACE and As-Treated Analysis

9. Conclusions/Clinical Pearls

10. Exploring the Safety of P2Y12 Inhibitors in STEMI Patients Receiving Fibrinolytic Therapy

11. TREAT Study Fills PLATO Study Gap

12. TREAT Trial: Design and Methods

13. TREAT Trial: Results

14. TREAT Study: Principal Findings (30 Days)

15. Conclusions/Clinical Pearls

16. The Correlation Between Prescription Supply and Medication Adherence After Acute Myocardial Infarction

17. 30- vs 90-Day Prescription Supply Study: Background and Methods

18. 30- vs 90-Day Prescription Supply Study: Results

19. 30- vs 90-Day Prescription Supply Study: Results (Baseline Characteristics)

20. 30- vs 90-Day Prescription Supply Study Results (Adherence and Product Changes)

21. Study Limitations

22. Conclusions/Clinical Pearls

23. The Clinical Implications of De-Escalating Antiplatelet Therapy

24. DAPT Guideline Recommendations

25. The Concept of De-Escalation

26. Prevalence and Timing of De-Escalation Therapy in Patients With ACS

27. Clinical Outcomes Associated With De-Escalation Therapy

28. SWAP-4 Study Design

29. SWAP-4 Study: Results and Conclusions

30. Conclusions/Clinical Pearls

31. Abbreviations

32. Abbreviations (cont)